Avoid prophylactic platelet transfusions in asymptomatic thrombocytopenic patients with chronic bone marrow failure who are not receiving intensive chemotherapy. Exercise particular restraint in the end-of-life phase

Rationale: 

Studies of different transfusion practices support a restrictive transfusion strategy. Such an approach reduces transfusion reactions and alloimmunization, alleviates shortages of platelet concentrates, and lowers costs and staffing demands. Platelets have a short lifespan, necessitating frequent transfusions. This results in repeated travel to the hospital for patients and significant time away from home and daily activities.
 
Reference: 

• Platelet Transfusion 2025 AABB and ICTMG International Clinical Practice Guidelines og Guidelines for the use of platelet transfusions Estcourt BJHaem 2016 revidert 2022.